Toni Choueiri, MD· @DrChoueiri · X·· 1 天前评分45
正文 · 原文
And now @Maroto5Pablo reporting long term follow-up from phase Ib/II #EV-103 study.
Consistent with prior reports:
EV+P demonstrated sustained responses and survival, with a manageable safety profile.
#ESMO26 #Day2 @myESMO @OncoAlert
226 浏览 · 5 赞 · 4 转发 · 0 回复
会议摘要
4740RO按 Rapid oral 1: Genitourinary tumours, renal and urothelial 对上
Enfortumab Vedotin (EV) With or Without Pembrolizumab (P) as First-Line (1L) Treatment for Cisplatin (cis)-Ineligible Locally Advanced Or Metastatic Urothelial Carcinoma (la/mUC): Long-Term Follow-up Analysis from EV-103 Cohorts DE/A and K
https://esmocongress.esmo.org来源：Toni Choueiri, MD · x.com